ImmuPharma (LON:IMM) Trading Up 34.1% - Here's Why

Key Points

• ImmuPharma plc shares surged by 34.1% on Tuesday, reaching a high of GBX 11.50 ($0.16) with significant trading volume of over 57 million shares.
• The company has a market cap of £54.02 million and reported earnings per share of GBX (0.38) in its last quarterly earnings.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program being P140 (Lupuzor™) for the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) was up 34.1% during mid-day trading on Tuesday . The company traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares were traded during trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Price Performance

The stock's 50-day moving average is GBX 2.72 and its 200-day moving average is GBX 2.82. The stock has a market cap of £50.97 million, a price-to-earnings ratio of -1,146.07 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.